Zymeworks Inc. Common Stock (ZYME) - Total Liabilities

Latest as of September 2025: $77.20 Million USD

Based on the latest financial reports, Zymeworks Inc. Common Stock (ZYME) has total liabilities worth $77.20 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Zymeworks Inc. Common Stock to track the company's year-over-year net asset growth rate.

Zymeworks Inc. Common Stock - Total Liabilities Trend (2014–2024)

This chart illustrates how Zymeworks Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Zymeworks Inc. Common Stock generate to measure how efficiently the company converts operating cash flow to free cash.

Zymeworks Inc. Common Stock Competitors by Total Liabilities

The table below lists competitors of Zymeworks Inc. Common Stock ranked by their total liabilities.

Company	Country	Total Liabilities
Blackline Inc NASDAQ:BL	USA	$1.12 Billion
Grupo Televisa SAB ADR NYSE:TV	USA	$122.08 Billion
Killam Apartment Real Estate Investment Trust TO:KMP-UN	Canada	CA$2.48 Billion
Pfeiffer Vacuum Technology AG F:PFV	Germany	€424.22 Million
Peugeot Invest SA PA:PEUG	France	€1.19 Billion
LuxNet TWO:4979	Taiwan	NT$1.64 Billion
Citic Offshore Helicopter Co Ltd SHE:000099	China	CN¥1.90 Billion
Xinhuanet Co Ltd SHG:603888	China	CN¥1.25 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down Zymeworks Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Zymeworks Inc. Common Stock (ZYME) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	6.94	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.24	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.19	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Zymeworks Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Zymeworks Inc. Common Stock (2014–2024)

The table below shows the annual total liabilities of Zymeworks Inc. Common Stock from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	$124.32 Million	+7.11%
2023-12-31	$116.07 Million	-25.48%
2022-12-31	$155.77 Million	+11.23%
2021-12-31	$140.04 Million	+9.02%
2020-12-31	$128.45 Million	+4.84%
2019-12-31	$122.52 Million	+91.82%
2018-12-31	$63.87 Million	+311.37%
2017-12-31	$15.53 Million	-81.73%
2016-12-31	$84.99 Million	+1631.02%
2015-12-31	$4.91 Million	-54.97%
2014-12-31	$10.90 Million	--

About Zymeworks Inc. Common Stock

NASDAQ:ZYME USA Biotechnology

Market Cap

$1.64 Billion

Market Cap Rank

#6763 Global

#2100 in USA

Share Price

$21.94

Change (1 day)

-3.39%

52-Week Range

$12.02 - $28.56

All Time High

$56.81